SI
SI
discoversearch

Biotech / Medical
Incyte Pharmaceuticals (INCY)
An SI Board Since January 1996
Posts SubjectMarks Bans Symbol
3033 142 0 INCY
Emcee:  ANGELIQUE LEE Type:  Unmoderated
INCY is involved in the mapping of the human genome and is supported by many major pharmeceutical companies. I bought in at 28 as a long-term buy when they started trading on the NASDAQ last week. They ahve been moving quite a bit since then, breaking new highs at closing all week. Friday their day low was 30, day high of 36. Anybody have recent info that might explain the fluctuation? Thanks, Angelique
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
3033GILD - Idelalisib INCY - INCB40093 TGTX - TGR-1202 INFI - IPI-145 and IPI-443 scaram(o)uche-yesterday
3032BRUSSELS, Aug 8 (Reuters) - Belgian biotech group Galapagos said its partner Glanigel bates-August 8
3031I did substantially increase my GILD position, but lost out on INCY and TGTX, a Biotech Jim-June 18
3030This list back in play? Wouldn't it be surprising if GILD ended up in the cscaram(o)uche-June 16
3029 NEW YORK & WILMINGTON, Del.--(BUSINESS WIRE)-- Bristol-Myers Squibb Companynigel bates-May 27
3028"c-reactive proteins levels greater than 13 mg/dl" thestreet.comscaram(o)uche-May 14
3027Incyte Corporation ( INCY) and MedImmune, the global biologics research and devenigel bates-May 14
3026ditto, HER2-negative breast.... clinicaltrials.gov Be interesting to see if GIscaram(o)uche-April 23
3025>> And it _is_ rux's rolling rock, rather than 110's or 986's scaram(o)uche-April 23
3024As everyone here probably knows, title abstracts (minus late breakers) are out fscaram(o)uche-April 22
3023>> Gilead isn't letting cyt-387 moss grow under rux's rolling rockscaram(o)uche-April 21
3022#2 was first from this Zach guy, who is quite good, a week ago. So, my news is scaram(o)uche-April 9
3021Hey! Hope everyone is well/thriving! >> Not sure where I'd buy back scaram(o)uche-April 9
3020Top line results of ruxolitinib in PV; hits primary endpoint in P3: >>Martuck-April 8
3019On the INCY competition front... "Galapagos NV ( GLPGF) announced today thBiotech Jim-February 28
3018Probably a coincidence. Musings on MRK's MK-3475 deals announced today: inDewDiligence_on_SI-February 5
3017Noticed a concomitant movement of the release of this news and the dive of the sD.Lu-February 5
3016From Practice Update, an oncology journal updater that I subscribe to. The NatuBiotech Jim-January 28
3015Does anyone have any thoughts, input or info on the Ruxo Phase 2 PanCa subgroup,quantman-January 16
3014<Any speculation why Friedman resigned? He did present at JP Morgan.> LoBiotech Jim-January 14
3013Incyte announces the appointment of former Novartis Oncology president HervéD.Lu-January 14
3012Paul Friedman will present at JP Morgan Healthcare Conference on Monday, Jan 13D.Lu-January 2
3011>> a 093 plus ruxolitinib combo, lymphoma, seemed like a telegraphed next-scaram(o)uche-12/23/2013
3010Fast, indeed, at 3 months. I gather that is as mature as their data gets at thituck-12/10/2013
3009First, thanks for pointing me to that poster/graphic. Hadn't seen it, only scaram(o)uche-12/10/2013
3008OK, thanks, but look at my edit. I gather you already found the Incyte results tuck-12/10/2013
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
Copyright © 1995-2014 Knight Sac Media. All rights reserved.Stock quotes are delayed at least 15 minutes - See Terms of Use.